Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats - PubMed (original) (raw)
Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats
Christoph Wiessner et al. J Cereb Blood Flow Metab. 2003 Feb.
Abstract
Nogo-A is a myelin-associated neurite outgrowth inhibitory protein limiting recovery and plasticity after central nervous system injury. In this study, a purified monoclonal anti-Nogo-A antibody (7B12) was evaluated in two rat stroke models with a time-to-treatment of 24 hours after injury. After photothrombotic cortical injury (PCI) and intraventricular infusion of a control mouse immunoglobulin G for 2 weeks, long-term contralateral forepaw function was reduced to about 55% of prelesion performance until the latest time point investigated (9 weeks). Forepaw function was significantly better in the 7B12-treated group 6 to 9 weeks after PCI, and reached about 70% of prelesion levels. Cortical infarcts were also produced in spontaneously hypertensive rats (SHR) by permanent middle cerebral artery occlusion (MCAO). In the control group, forepaw function remained between 40% and 50% of prelesion levels 4 to 12 weeks after MCAO. In contrast, 7B12-treated groups showed significant improvement between 4 and 7 weeks after MCAO from around 40% of prelesion levels at week 4 to about 60% to 70% at 7 to 12 weeks after MCAO. Treatment in both models was efficacious without influencing infarct volume or brain atrophy. Neuroanatomically in the spinal cord, a significant increase of midline crossing corticospinal fibers originating in the unlesioned sensorimotor cortex was found in 7B12-treated groups, reaching 2.3 +/- 1.5% after PCI (control group: 1.1 +/- 0.5%) and 4.5 +/- 2.2% after MCAO in SHR rats (control group: 1.8 +/- 0.8%). Behavioral outcome and the presence of midline crossing fibers in the cervical spinal cord correlated significantly, suggesting a possible contribution of the crossing fibers for forepaw function after PCI and MCAO. The results suggest that specific anti-Nogo-A antibodies bear potential as a new rehabilitative treatment approach for ischemic stroke with a prolonged time-to-treatment window.
Similar articles
- Rewiring of the corticospinal tract in the adult rat after unilateral stroke and anti-Nogo-A therapy.
Lindau NT, Bänninger BJ, Gullo M, Good NA, Bachmann LC, Starkey ML, Schwab ME. Lindau NT, et al. Brain. 2014 Mar;137(Pt 3):739-56. doi: 10.1093/brain/awt336. Epub 2013 Dec 18. Brain. 2014. PMID: 24355710 Clinical Trial. - Constraint-induced movement therapy overcomes the intrinsic axonal growth-inhibitory signals in stroke rats.
Zhao S, Zhao M, Xiao T, Jolkkonen J, Zhao C. Zhao S, et al. Stroke. 2013 Jun;44(6):1698-705. doi: 10.1161/STROKEAHA.111.000361. Epub 2013 Apr 30. Stroke. 2013. PMID: 23632976 - Delayed treatment with monoclonal antibody IN-1 1 week after stroke results in recovery of function and corticorubral plasticity in adult rats.
Seymour AB, Andrews EM, Tsai SY, Markus TM, Bollnow MR, Brenneman MM, O'Brien TE, Castro AJ, Schwab ME, Kartje GL. Seymour AB, et al. J Cereb Blood Flow Metab. 2005 Oct;25(10):1366-75. doi: 10.1038/sj.jcbfm.9600134. J Cereb Blood Flow Metab. 2005. PMID: 15889044 - Neuronal plasticity and functional recovery after ischemic stroke.
Cheatwood JL, Emerick AJ, Kartje GL. Cheatwood JL, et al. Top Stroke Rehabil. 2008 Jan-Feb;15(1):42-50. doi: 10.1310/tsr1501-42. Top Stroke Rehabil. 2008. PMID: 18250073 Review. - Therapeutics targeting Nogo-A hold promise for stroke restoration.
Kumar P, Moon LD. Kumar P, et al. CNS Neurol Disord Drug Targets. 2013 Mar;12(2):200-8. doi: 10.2174/1871527311312020006. CNS Neurol Disord Drug Targets. 2013. PMID: 23394537 Free PMC article. Review.
Cited by
- Out of the core: the impact of focal ischemia in regions beyond the penumbra.
Koukalova L, Chmelova M, Amlerova Z, Vargova L. Koukalova L, et al. Front Cell Neurosci. 2024 Mar 5;18:1336886. doi: 10.3389/fncel.2024.1336886. eCollection 2024. Front Cell Neurosci. 2024. PMID: 38504666 Free PMC article. Review. - Anti-Nogo-A Antibody Therapy Improves Functional Outcome Following Traumatic Brain Injury.
Powers BE, Ton ST, Farrer RG, Chaudhary S, Nockels RP, Kartje GL, Tsai SY. Powers BE, et al. Neurorehabil Neural Repair. 2023 Oct;37(10):682-693. doi: 10.1177/15459683231203194. Epub 2023 Oct 14. Neurorehabil Neural Repair. 2023. PMID: 37837331 Free PMC article. - Corticospinal tract: a new hope for the treatment of post-stroke spasticity.
Huang L, Yi L, Huang H, Zhan S, Chen R, Yue Z. Huang L, et al. Acta Neurol Belg. 2024 Feb;124(1):25-36. doi: 10.1007/s13760-023-02377-w. Epub 2023 Sep 13. Acta Neurol Belg. 2024. PMID: 37704780 Free PMC article. Review. - Advances in Antibody-Based Therapeutics for Cerebral Ischemia.
Sun JM, Yen TL, Jan JS, Mwale PF, Teng RD, Taliyan R, Hsieh CT, Yang CH. Sun JM, et al. Pharmaceutics. 2022 Dec 31;15(1):145. doi: 10.3390/pharmaceutics15010145. Pharmaceutics. 2022. PMID: 36678774 Free PMC article. Review. - Neural recovery after cortical injury: Effects of MSC derived extracellular vesicles on motor circuit remodeling in rhesus monkeys.
Calderazzo S, Covert M, Alba D, Bowley BE, Pessina MA, Rosene DL, Buller B, Medalla M, Moore TL. Calderazzo S, et al. IBRO Neurosci Rep. 2022 Aug 18;13:243-254. doi: 10.1016/j.ibneur.2022.08.001. eCollection 2022 Dec. IBRO Neurosci Rep. 2022. PMID: 36590089 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous